NCT02298959 2026-03-18
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
13 trialsNCT02159989 2025-10-20
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT03730558 2025-01-22
ZETA
Institut Sainte Catherine
Completed
NCT01782443 2023-08-14
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02181556 2021-06-07
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT01669720 2020-02-17
C261
Brown University
Phase 2 Terminated
NCT01661972 2018-10-29
X-TRAP
Duke University
Phase 1/2 Completed
NCT03264274 2017-08-31
AUSCOR
Barts & The London NHS Trust
Phase 2 Withdrawn
NCT02045030 2016-11-16
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
Phase 2 Terminated
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT00284141 2012-12-10
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
Sanofi
Phase 2 Completed
NCT00921661 2012-11-09
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
Sanofi
Phase 1 Completed
NCT00561470 2012-09-28
VELOUR
Sanofi
Phase 3 Completed